Staar Surgical's China ICL Demand Driven by Macro Affordability Pressures, Wedbush Says

MT Newswires Live07-15

Staar Surgical's (STAA) implantable collamer lens demand in China appears to be driven by macro affordability pressures rather than a shift in physician or patient preference toward laser-based alternatives, while US adoption remains constrained by a multi-year surgeon-training pipeline rather than a product or marketing failure, Wedbush Securities said Wednesday.

"The Collamer/EVO reputational moat was independently corroborated by all sources, which gives us confidence that STAA has a competitive advantage versus local Chinese entrants," the report said.

Wedbush said China's domestic entrant, EyeBright, represents the clearest incremental risk, as it could capture notably larger local market share over the next couple of years.

Wedbush believes Staar Surgical's dominant market position in phakic IOLs, continued growth outside of China, proprietary technology, and favorable long-term industry dynamics offer multiple paths to value creation.

Wedbush kept an outperform rating on Staar Surgical with a price target of $40.

Price: 27.94, Change: +0.60, Percent Change: +2.19

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment